Page 32 - Patco News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patco. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patco Today - Breaking & Trending Today

Natco Pharma signs pact with Eli Lilly for COVID drug in India


The drug maker signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for COVID-19 indication in India.
In line with the licensing agreement, Natco Pharma has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India.
Natco Pharma had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). ....

Eli Lilly , Natco Pharma , Indian Patent Office , Central Drugs Standard Control Organization , Compulsory License , Capital Market , Chemical Compounds , Health Sciences , Organic Compounds , Breakthrough Therapy , Eli Lilly And Company , Pharmaceutical Industry , Eli Lilly , Royalty Payment , Harmaceuticals Nec , Central Drugs , எலி லில்லி , நாட்கோ பார்மா , இந்தியன் காப்புரிமை அலுவலகம் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , கட்டாய உரிமம் , மூலதனம் சந்தை , இரசாயன கலவைகள் ,

Eli Lilly inks pact with Natco Pharma for COVID drug baricitinib


Natco Pharma to further expedite the availability of
baricitinib for COVID-19 patients in India.
The company has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma and the Hyderabad-based company will be collaborating with Eli Lilly to further accelerate and expand the availability of baricitinib in India during this pandemic.
The move will improve the local treatment options available and will positively impact the lives of people who are currently battling COVID-19 in India, Eli Lilly said in a statement.
Earlier, the company had announced signing of six voluntary license agreements with
Cipla, Lupin, Sun Pharmaceutical Industries, Dr Reddy s, MSN Laboratories and Torrent Pharmaceuticals. ....

Andhra Pradesh , Anju Narayanan , Eli Lilly , Raman Mehta , Natco Pharma , Group Cmdm Sn Reddy , Torrent Pharmaceuticals , Sun Pharmaceutical Industries , Central Drugs Standard Control Organization , Direct Relief , Torrent Pharma , Eli Lilly , Covid 19 , ஆந்திரா பிரதேஷ் , அஞ்சு நாராயணன் , எலி லில்லி , ஒரு மனிதன் மேத்தா , நாட்கோ பார்மா , நீரோடை மருந்துகள் , சூரியன் மருந்து தொழில்கள் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , நேரடி துயர் நீக்கம் , நீரோடை பார்மா ,

Natco Pharma rallies 7% as firm seeks nod for Covid medicine Molnupiravir


Investors rushed to pick shares of Natco Pharma on the BSE on Monday as the firm sought Central Drugs Standard Control Organization s (CDSCO s) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients. At 11:30 am, shares of the pharmaceutical firm were ruling 5 per cent higher on the BSE, at Rs 923 apiece, as against a 1.4 per cent rise in the benchmark S&P BSE Sensex. In the intra-day deals, the shares surged 7.5 per cent to Rs 944 per share on the BSE.
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, the firm said in an exchange filing. ....

Natco Pharma , Central Drugs Standard Control Organization , Molnupiravir Capsules , Natco Pharma , Natco Pharma Share Price , Covid 19 , Covid 19 Medicine , நாட்கோ பார்மா , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் ,